Loading
Latest filing published 01 Oct 2026 for Zentalis Pharmaceuticals, Inc., €19k.
Not enough history yet: 1 closed purchase, at least 2 are needed.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This profile gathers the share dealings of Ingmar Bruns in Zentalis Pharmaceuticals, Inc. Between 3 February 2025 and 30 September 2026, the trades on record add up to 5 filings.
Both buying and selling appear: 1 purchase worth €44k, against 2 sales worth €6,787. Netting one side against the other leaves €37k of net buying. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Outside the open market, there are 2 share grants. So far in 2026, the count stands at no purchases and 2 sales.
The record was last updated on 1 October 2026 with a share grant (€19k) in Zentalis Pharmaceuticals, Inc. The last purchase on record was published on 12 February 2025, which is 619 days ago. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
4 of 4 declarations